Form 4: Natera Co-Founder Jonathan Sheena Reports Routine Stock Transactions

Natera Co-Founder and Director Jonathan Sheena reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, executed under a pre-arranged trading plan.

Summary

• Jonathan Sheena, Co-Founder and Director of Natera, Inc., reported transactions involving Natera common stock.
• On July 20, 2025, 190 Restricted Stock Units (RSUs) vested, converting into 190 shares of Natera Common Stock.
• On July 21, 2025, 93 shares of Common Stock were sold at a price of $139.29 per share.
• The sale was conducted to satisfy tax withholding and remittance obligations related to the RSU vesting.
• The transactions were executed under a Rule 10b5-1(c) pre-arranged trading plan established on January 28, 2022.
• Following these transactions, Jonathan Sheena directly holds 245,801 shares of Natera Common Stock.
• Additionally, 35,782 shares are held indirectly by the Caraluna 1 Trust and 35,782 shares by the Caraluna 2 Trust, though Mr. Sheena disclaims beneficial ownership of these trust-held shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and subsequent tax-related sale) executed under a pre-arranged plan. This is a neutral event, not indicative of positive or negative company performance or insider sentiment beyond standard compensation practices.

Positives

• Transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned, non-discretionary sales for tax purposes rather than a discretionary sale based on market outlook.
• The vesting of Restricted Stock Units indicates continued compensation and retention of a key co-founder and director.

Negatives

• A sale of shares by an insider, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report for a biotechnology company, Natera, Inc., which specializes in genomics. Such transactions are common across all industries when executives receive equity compensation that vests and requires tax payments.

Related Party Transactions

• Shares are held indirectly for the benefit of the beneficiaries of the Caraluna 1 Trust and Caraluna 2 Trust, with the Reporting Person disclaiming beneficial ownership.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is offset by the routine nature of the transaction. The sale for tax purposes is a standard event and does not signal a change in insider confidence.
• Employees: The RSU vesting demonstrates the company's compensation structure for key personnel.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest in 12 equal quarterly installments following January 20, 2023.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned transaction by a co-founder and director to cover tax obligations arising from RSU vesting. It does not provide new information regarding Natera's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is a standard event for executives receiving equity compensation and does not reflect a discretionary decision to sell based on company outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Natera, NTRA, Jonathan Sheena, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Rule 10b5-1, Biotechnology, Genomics